Shares of Cleveland BioLabs Inc. (NASDAQ:CBLI) traded down 10.3% during mid-day trading on Tuesday . The company traded as low as $2.08 and last traded at $2.08, with a volume of 61,997 shares trading hands. The stock had previously closed at $2.32.

The stock’s market cap is $23.51 million. The stock’s 50 day moving average price is $2.61 and its 200-day moving average price is $2.68.

Cleveland BioLabs (NASDAQ:CBLI) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.17) earnings per share for the quarter. On average, equities analysts predict that Cleveland BioLabs Inc. will post ($0.16) EPS for the current year.

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.